Expanded Use for ImmunityBio Drug
ImmunityBio secured FDA approval to expand its flagship drug Anktiva for a more prevalent type of bladder cancer. The Culver City immunotherapy firm received the green light on Oct. 14, several months before the agency’s scheduled decision date. The news sent the company’s stock price higher, signaling strong market confidence in its growth prospects.
Read the full story at Los Angeles Business Journal →
Summary written by Entrepreneurs Of Los Angeles. The original reporting belongs to Los Angeles Business Journal; we do not republish the article.